Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: Cancer of the Breast, Chemotherapy-induced Neuropathy
Interventions: Tango; Behavioral
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 40 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: New Haven, Connecticut • Columbus, Ohio

Conditions: Psoriatic Arthritis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 489 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 17
States / cities: Phoenix, Arizona • Colorado Springs, Colorado • Bridgeport, Connecticut + 14 more

Conditions: Diabetes Mellitus, Type 2
Interventions: albiglutide + insulin glargine, insulin glargine + preprandial lispro insulin; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 142
States / cities: Birmingham, Alabama • Dothan, Alabama • Gilbert, Arizona + 119 more

Conditions: Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Interventions: NT 201, Placebo; Drug
Lead sponsor: Merz North America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 12
States / cities: Encino, California • Newport Beach, California • San Diego, California + 7 more

Conditions: Bruxism
Interventions: Botulinum toxin type A, Placebo arm; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Left Ventricular Dysfunction
Interventions: Adult stem cells, Placebo; Biological
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 21 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 5
States / cities: Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more

Conditions: Intermittent Claudication, Peripheral Vascular Disease, Atherosclerosis
Interventions: Ad2/HIF-1α/VP16, Saline (Placebo Control); Biological · Other
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 35
States / cities: Birmingham, Alabama • Palo Alto, California • Sacramento, California + 28 more

Conditions: Cervical Dystonia
Interventions: Botulinum toxin type A, Placebo; Biological · Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 42
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 35 more

Conditions: Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
Interventions: Durvalumab, Standard Chemotherapy, Ipilimumab and Nivolumab; Drug
Lead sponsor: PrECOG, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 25
States / cities: La Jolla, California • Miami, Florida • Tampa, Florida + 20 more

Conditions: Major Depressive Disorder
Interventions: Creatine monohydrate or placebo; Drug
Lead sponsor: Perry Renshaw; Other
Eligibility: 13 Years to 21 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hernia Abdominal Wall, Botox Injection, Hernia Incisional Ventral, Hernia Repair With Compartment Syndrome, Hernia Surgery, Hernia, Hernia Incisional
Interventions: OnabotulinumtoxinA Injection, Saline (placebo) Injection, OnabotulinumtoxinA, 0.9 % Normal Saline, Open Ventral Hernia Repair; Procedure · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Post-stroke Shoulder Pain and Spasticity
Interventions: Botulinum Toxin Type A - OnabotulinumtoxinA, Placebo (Saline); Drug
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anemia
Interventions: Epoetin alfa or beta, RO0503821 (1x/2 Weeks), RO0503821 (1x/4 Weeks); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 673 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 60
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 51 more

Conditions: Gestational Diabetes
Interventions: Glyburide, Insulin; Drug
Lead sponsor: Tripler Army Medical Center; Federal
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Enterovirus Infection
Interventions: EV68-228-N, Placebo for EV68-228-N; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Baltimore, Maryland • Nashville, Tennessee

Conditions: Infertility, Endometriosis
Interventions: Elagolix 200 MG, Leuprolide Acetate 3.75 MG/ML, Lab work; Drug · Diagnostic Test
Lead sponsor: Colorado Center for Reproductive Medicine; Other
Eligibility: 21 Years to 42 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Lone Tree, Colorado

Conditions: Congenital Heart Disease, Hypoplastic Left Heart Syndrome, Transposition of the Great Arteries, Aortic Arch Hypoplasia or Interruption
Interventions: Erythropoetin, Normal saline; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Day to 30 Days
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Endometrial Dysfunction
Interventions: Estradiol Valerate, Progesterone in Oil, Leuprolide; Other
Lead sponsor: Reproductive Medicine Associates of New Jersey; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Basking Ridge, New Jersey

Conditions: Obesity
Interventions: Lorcaserin 10 mg BID, Matching Placebo BID; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 3,182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Haemostasis, Healthy
Interventions: eptacog alfa (activated), clopidogrel, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Heart Failure
Interventions: Thyroid hormone T3, Control Group; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Multiple Sclerosis
Interventions: Teriflunomide, Placebo (for Teriflunomide), Interferon-β; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Cervical Ripening, Induction of Labor, Multiparity
Interventions: Oxytocin; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells; Drug · Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 58 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY

Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis

A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines

Study of the Safety and Efficacy of Botox in Bruxism

Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)

Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication

Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.

DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Dose-Ranging Trial of Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder

Preoperative BOTOX® Injection for Large Ventral Hernia Repair

Randomized DB Controlled Trial of Botulinum Toxin A in Hemiplegic Shoulder Pain and Spasticity

A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Glyburide Compared to Insulin in the Management of White's Classification A2 Gestational Diabetes

Phase 1, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of an Enterovirus D68-specific Monoclonal Antibody in Healthy Adults

Comparison Elagolix vs Depot Leuprolide Prior to Frozen Embryo Transfers in Patients With Endometriosis

Erythropoetin Neuroprotection for Neonatal Cardiac Surgery

Endometrial Receptivity Profile in Patients With Endometrial Proliferation Defects

BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management

Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding

Effects of Triiodothyronine (T3) in Ischemic Heart Failure

Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis

Study of the Effectiveness of Cervical Ripening Balloon With and Without Oxytocin

Maximizing Outcome of Multiple Sclerosis Transplantation